Richard A. Larson, MD, is director of the Hematologic Malignancies Clinical Research Program at the University of Chicago. He was the director of the Leukemia Clinical Research Program from 1983 to 2000, during which time he established the medical center's allogeneic blood and marrow transplant program.
Dr. Larson maintains an active clinical practice at the University of Chicago Medicine, and his expertise is widely sought for consultations regarding leukemias and myelodysplastic syndromes.
His current research interests include clinical trials in hematologic malignancies and stem cell transplantation, experimental therapeutics, the determinants of response to therapy in leukemia and myelodysplastic syndromes, and the etiology of therapy-related leukemias.
Dr. Larson is the past chairman of the Leukemia Committee of the Cancer and Leukemia Group B where he directed a large portfolio of clinical trials and ancillary laboratory studies in acute and chronic leukemias. He has also served as a member of the Hematology Subspecialty Board of the American Board of Internal Medicine.
An active researcher, Dr. Larson has published more than 400 papers, reviews, and book chapters on clinical and laboratory studies in human leukemias. He has served on the editorial boards of BLOOD, the Journal of Clinical Oncology and Leukemia.
He also actively participates in the training of 21 fellows in Hematology/Oncology within the Department of Medicine.
Dr. Larson maintains an active clinical practice at the University of Chicago Medicine, and his expertise is widely sought for consultations regarding leukemias and myelodysplastic syndromes.
His current research interests include clinical trials in hematologic malignancies and stem cell transplantation, experimental therapeutics, the determinants of response to therapy in leukemia and myelodysplastic syndromes, and the etiology of therapy-related leukemias.
Dr. Larson is the past chairman of the Leukemia Committee of the Cancer and Leukemia Group B where he directed a large portfolio of clinical trials and ancillary laboratory studies in acute and chronic leukemias. He has also served as a member of the Hematology Subspecialty Board of the American Board of Internal Medicine.
An active researcher, Dr. Larson has published more than 400 papers, reviews, and book chapters on clinical and laboratory studies in human leukemias. He has served on the editorial boards of BLOOD, the Journal of Clinical Oncology and Leukemia.
He also actively participates in the training of 21 fellows in Hematology/Oncology within the Department of Medicine.
Specialties
Areas of Expertise
Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
Memberships & Medical Societies
- American Association for Cancer Research
- American Society of Hematology
- American Society of Clinical Oncology
Practicing Since
- 1977
Languages Spoken
- English
Medical Education
- Stanford University School of Medicine
Residency
- University of Chicago Medicine
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
- Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
- Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
- Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
- Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
- Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient